Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Hub
News
Changes
Search
Log in
Get Started
BYQLOVI (CLOBETASOL PROPIONATE) | LOERadar
Viewing data from:
Latest
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
BYQLOVI
NDA
Get alerts
CLOBETASOL PROPIONATE | N218158 | HARROW EYE LLC
1 strength
2 unique patents
1 unique exclusivity
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
DMF
Approvals
Label
Products
Patent Timeline
2 unique patents, 1 exclusivity by expiration date
Active (2)
Today
Exclusivity
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
Today
10588913
May. 9, 2036
11376262
May. 9, 2036
NP
Mar. 4, 2027
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (1)
#001 — 0.05%
RLD
2 patents
1 exclusivity
▴
SUSPENSION/DROPS;OPHTHALMIC | Approved: Mar 4, 2024
Patents (2)
Patent #
Expiration
PED
Drug Substance
Drug Product
Use Code
Delist
10588913
May 9, 2036
—
—
Yes
—
—
11376262
May 9, 2036
—
—
Yes
U-19
TREATMENT OF INFLAMMATION
—
Exclusivities (1)
Code
Date
Status
NP
Mar 4, 2027
< 1 year